Naka Go, Yokoyama Takuma, Usui Kazuhiro, Ishida Hiroo, Kishi Kazuma, Uemura Kohei, Ohashi Yasuo, Kunitoh Hideo
National Center for Global Health and Medicine, Tokyo, Japan.
Kyorin University Hospital, Mitaka, Tokyo, Japan.
Jpn J Clin Oncol. 2022 Jul 8;52(7):791-794. doi: 10.1093/jjco/hyac032.
Osimertinib is active against T790M-positive epidermal growth factor receptor mutant non-small cell lung cancer. We enrolled 122 sensitive epidermal growth factor receptor mutant non-small cell lung cancer patients who were planned to receive or were receiving first-/second-generation epidermal growth factor receptor tyrosine kinase inhibitors without disease progression and monitored plasma T790M every 1-2 months using the cobas® EGFR Mutation Test v2. We previously reported the concordance between T790M status in plasma and tissue. This is the final report on the sensitivity of plasma T790M and the efficacy of sequential osimertinib. The sensitivity was 21.1% (95% confidence interval: 6.1-45.6%). The best overall response was 25.0% (95% confidence interval: 9.8-46.7) in the plasma T790M-positive group and 28.6% (95% confidence interval: 8.4-58.1) in the plasma T790M-negative but tissue T790M-positive group. Median progression-free survival was 7.9 months (95% confidence interval: 4.7-17.5) for the former and 4.4 months (95% confidence interval: 3.0-N.E.) for the latter, with no statistically significant difference (P = 0.74).
奥希替尼对T790M阳性的表皮生长因子受体突变型非小细胞肺癌有效。我们纳入了122例敏感的表皮生长因子受体突变型非小细胞肺癌患者，这些患者计划接受或正在接受第一代/第二代表皮生长因子受体酪氨酸激酶抑制剂且无疾病进展，每1 - 2个月使用cobas® EGFR Mutation Test v2监测血浆T790M。我们之前报道了血浆和组织中T790M状态的一致性。这是关于血浆T790M敏感性及序贯使用奥希替尼疗效的最终报告。敏感性为21.1%（95%置信区间：6.1 - 45.6%）。血浆T790M阳性组的最佳总体缓解率为25.0%（95%置信区间：9.8 - 46.7），血浆T790M阴性但组织T790M阳性组为28.6%（95%置信区间：8.4 - 58.1）。前者的中位无进展生存期为7.9个月（95%置信区间：4.7 - 17.5），后者为4.4个月（95%置信区间：3.0 - 无数据），差异无统计学意义（P = 0.74）。
